94 results about "Cerebral vascular accident" patented technology

The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Novel compounds of structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The invention relates to a Chinese medicine composition used in a hypertension-relieving and tranquilizing pillow, which belongs to the field of bed health-care products. The technical proposal thereof is: the composition comprises the raw materials with the following weight portion: 15 portions to 20 portions of Bluish dogbane, 20 portions to 30 portions of Semen Cassiae Torae, 10 portions to 20 portions of Rhizoma Ligustici Wallichii, 10 portions to 20 portions of Tree Peony Bark, 10 portions to 20 portions of Angelica dahurica, 10 portions to 20 portions of asarum, 10 portions to 20 portions of Selfheal, 5 portions to 10 portions of Borneol, 15 portions to 20 portions of Chinese Angelica, 15 portions to 25 portions of Cortex Eucommiae, 10 portions to 20 portions of Honeysuckle, 20 portions to 30 portions of flower of Chinese Scholartree, 20 portions to 40 portions of Mulberry leaf, 50 portions to 80 portions of Silkworm dropping, 15 portions to 25 portions of Gardenia Jasminoides, 10 portions to 20 portions of Rhizoma Gastrodiae, 10 portions to 20 portions of Radix Cyathulae, 10 portions to 20 portions of Radices Paeoniae Alba, 10 portions to 30 portions of Virgate Wormwood Herb and 15 portions to 30 portions of dried Rehmannia root. The formula is reasonable and the effects of activating blood circulation to dissipate blood stasis and dredging channels and collaterals as well as relieving hypertension and tranquilizing are remarkable. In addition, the Chinese medicine composition can prevent dizziness and headache caused by the elevation of blood pressure and diseases that threaten life such as cerebral vascular accident and cerebral thrombosis, and has remarkable effect on preventing cervical spondylosis.

A method for repairing animal tissue damage due to an inflammatory reaction in an animal has the steps of providing umbilical cord blood cells (UCBCs) in a pharmaceutically acceptable form; and administering a sufficient dose of UCBC at an optimal time thereby reducing the injury from the inflammatory reaction. Also provided are method of treating cerebrovascular accident, acute central nervous inflammation, multiple sclerosis, myocardial ischemia, and neonatal bronchopulmonary distress. For determining the optimal time of UCBCs administration, there is provided a kit containing antibodies for IL-8 and MCP-1.

Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

The invention relates to a traditional Chinese medicine for treating cardiac, cerebral and vascular diseases; the drug is composed of forty kinds of crude drugs by weight parts: milk veteh, salvia miltiorrhiza, root of common peony, ligusticum wallichii, lumbricus, sanguisuga, rhizoma acori graminei, polygala root, red ocher, oyster, angelica, the root of kudzu vine, arisaema cum bile and the like; the preparation method is that: (1) the crude drugs are prepared into water extract liquid; (2) the water extract liquid is prepared into oral liquid; (3)the water extract liquid obtained by the step (1) is dried, crushed, sieved, undersize material is extracted powder; (4) the extracted powder prepared by the step (3) is prepared into various dosage forms. The preparation method of crude powder is that: lime earth of the crude drugs is sieved, and then the crude drugs are crushed and sieved, the undersize material is taken out and is sterilized to be crude powder, and the crude powder is prepared into various dosage forms. The traditional Chinese medicine has the major functions of treating miocardial infarction and angina caused by coronary heart disease, high blood pressure and cerebral thrombosis, hemiplegia, cerebral infarction, cerebrovascular accident, sequel of apoplexy and other symptoms, and the medicine has obvious effect on headache, dizziness and heart cerebrovascular diseases caused by high blood pressure and cerebral circulation insufficiency.

Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Disclosed are single nucleotide polymorphisms (SNIps) associated with breast cancer, lung cancer, prostate cancer, non-insulin dependent diabetes, end stage renal disease due to non-insulin dependent diabetes, hypertension, end stage renal disease F due to hypertension, myocardial infarction, colon cancer, hypertension, atherosclerotic peripheral vascular disease due to hypertension, cerebrovascular accident due to hypertension, cataracts due to hypertension, cardiomyopathy with hypertension, myocardial infarction due to hypertension, non-insulin dependent diabetes mellitus, atherosclerotic peripheral vascular disease due to non-insulin dependent diabetes mellitus, cerebrovascular accident due to non-insulin dependent diabetes mellitus, ischemic cardiomyopathy, ischemic cardiomyopathy with non-insulin dependent diabetes mellitus, myocardial infarction due to non-insulin dependent diabetes mellitus, atrial fibrillations without valvular disease, alcohol abuse, anxiety, asthma, chronic obstructive pulmonary disease. cholecystectomy, degenerative joint disease, end stage renal disease and frequent de-clots, end stage renal disease due to focal segmental glomerular sclerosis, end stage renal disease due to insulin dependent diabetes mellitus, or seizure disorder. Also disclosed are methods for using SNPs to determine susceptibility to these diseases; nucleotide sequences containing SNPs; kits for determining the presence of SNPs; and methods of treatment or prophylaxis based on the presence of SNPs.

Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I′ (SEQ ID NO: 1):or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the bioconjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Compositions and methods of using same are provided for the treatment of neurodegenerative disorders such as Glaucoma, Multiple Sclerosis, Myasthenia Gravis, Diabetic Neuropathy, Cerebrovascular accident, spinal cord injuries, ALS, Parkinson's disease and Idiopathic dementia.

The invention provides citicoline sodium tablets which are medicinal preparations for treating sequela of a nervous system caused by a craniocerebral injury or a cerebrovascular accident, and a preparation method thereof. Every 1,000 tablets comprise 100.0 to 300.0g of citicoline sodium, 20.0 to 70.0g of starch, 50.0 to 160.0g of microcrystalline cellulose, 0.6 to 3g of hydroxypropyl methyl cellulose, 1.7 to 5.5g of magnesium stearate, 0 to 10g of sodium starch glycolate and 0 to 6.0g of pregelatinized starch. The preparation method of the citicoline sodium tablets mainly comprises the steps of sieving, weighing, proportioning, premixing, preparing a soft material, preparing wet granules, drying, granulating, mixing, tabletting, performing aluminum-plastic-aluminum packaging and outer packaging and the like. The tablets prepared by the method have the advantages of high yield, low cost, accurate divided dose, relatively stable medicinal physicochemical property and longer storage period and are convenient to carry and use.

The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The present invention discloses achyranthes bidentata polypeptide, a production method and applications, and the achyranthes bidentata polypeptide is produced with the steps including polypeptide extraction, polypeptide separation, etc. The achyranthes bidentata polypeptide is used to the preparation of drugs and health products for treating peripheral nerve injuries, cerebrovascular accidents, ischemic brain injuries, cerebral traumas, optic nerve injuries, spinal cord injuries and central nervous system injuries, antiaging and preventing neurodegenerative diseases. Experiments prove that the extracted achyranthes bidentata polypeptide (protein) of the present invention has the effects of promoting the growth of nerves, preventing the fading of nerve cells and promoting the regeneration of injured nerves, the source of medicinal materials is single, the preparation method is advanced, the technique is reasonable, the ingredients of preparations are definite, safety is high, and pharmacological action is obvious.

Novel compounds of structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinsons disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

The invention discloses a body-building syrup, which is prepared from gen-seng, gastrodia tuber, Siberian solomonseal rhizome, Moruloidea, asparagus root, lilyturf root, achyranthes and cyathula root, wolferry fruit, prepared rhizome of rehmannia, dried rehmannia root, haw, rhizoma dioscoreae and bee honey through boiling, filtering and concentrating.

Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.

The invention provides a cyclic polypeptide of Formula I (SEQ ID NO: 1):X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13  Ior an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1, X3, X4, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention or bioconjugates thereof, and their therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

A Chinese medicine for preventing and treating coronary heart disease, angina pectoris and cerebrovascular accident is prepared from American ginseng, notoginseng, borneol and dalbergia wood.

The invention relates to an oral liquid for healing hemiplegia, which is prepared from the following raw materials in parts by weight: 90-180 of raw milkvetch root, 3-15 of Chinese angelica, 3-10 of red paeony root, 3-10 of earthworm, 3-10 of rhizome chuanxiong, 3-10 of peach seed, 3-10 of safflower, 5-15 of pueraria root, 2-5 of pseudo-ginseng, 8-15 of tall gastrodia tuber and 5-20 of zaocys dhumnade. Aiming at the etiology and pathogenesis of hemiplegia, the oral liquid is formed by scientifically matching primary components with secondary components in multiple factors and has the efficacies of tonifying qi and blood, promoting blood circulation and removing obstruction in channels, stanching, dispersing pathogenic wind, and the like. The oral liquid has the advantages of easily-obtained raw material, no toxic side effect and favorable rehabilitation effect, is prepared by a simple process and is convenient to take. By clinically implementing the test administration treatment on 863 hemiplegic patients suffering from cerebrovascular accident (stroke) for years, the oral liquid has remarkable curative effect for all the patients receiving the test administration treatment, wherein 820 patients are clinically healed; and the effective rate for treatment reaches 100 percent and the cure rate reaches 95 percent.

Provided by the present invention are methods of treating a variety of disorders including AIDS, arthritis (rheumatoid arthritis, osteoarthritis, spondyloarthropathies), antibiotic induced diarrheal diseases (Closbidium difficile), multiple sclerosis, osteoporosis, gingivitis, peptic ulcer disease, esophagitis, diabetes, retinitis, uveitis, reperfusion injury after myocardial infarction (MI) or cerebral vascular accident (CVA), aphthous ulcers (oral), atherosclerosis (plaque rupture), prevention of tumor metastases, asthma, preeclampsia, acute pancreatitis, psoriasis, infertility and allergic disorders such as rhinitis, conjunctivitis, and urticaria.